10:01 AM EST, 01/16/2025 (MT Newswires) -- Procept BioRobotics' ( PRCT ) estimate of its addressable market "is overly exaggerated," Spruce Point Capital Management said in a short report Thursday.

Spruce Point also said the company's claim that it will fundamentally change current benign prostatic hyperplasia protocols is "unrealistic, since there is no one-size-fits-all BPH treatment."

Procept BioRobotics ( PRCT ) didn't immediately respond to a request for comment from MT Newswires.

The company's shares were down 0.9% in recent trading.

Price: 77.64, Change: -0.67, Percent Change: -0.86